散发性阿尔茨海默病基于估计症状发作年数的生物标志物变化时间
研究利用淀粉样蛋白PET与时间关联的时钟,估算散发性阿尔茨海默病中血浆、脑脊液、影像和认知指标的变化时间。淀粉样蛋白PET阳性亚组118例,平均年龄70.4±7.4岁,16%存在认知障碍;阴性亚组277例。结果显示不同生物标志物在估计症状发作前7-19年出现变化。
要点
- 脑脊液Aβ42/Aβ40、血浆Aβ42/Aβ40、脑脊液pT217/T217和淀粉样蛋白PET在估计症状发作前15-19年出现变化。
- 血浆pT217/T217、脑脊液神经颗粒素、脑脊液SNAP-25、脑脊液sTREM2、血浆GFAP和血浆NfL在估计症状发作前12-14年出现变化。
- 脑脊液p205/T205、脑脊液YKL-40、海马体积和认知指标在估计症状发作前7-9年出现变化。
核心结论
- 基于淀粉样蛋白时钟的估计症状发作年数可作为散发性阿尔茨海默病的连续分期指标,并与常染色体显性阿尔茨海默病的研究发现一致。
研究设计与样本
- 纳入在淀粉样蛋白PET检查2年内接受脑脊液采集的研究参与者,估算每个个体的淀粉样蛋白发病年龄和阿尔茨海默病症状发作年龄,通过比较淀粉样蛋白PET阳性和阴性组的横断面数据限制性立方样条计算生物标志物变化时间。
- 淀粉样蛋白PET阳性亚组118例,平均年龄70.4±7.4岁(均值±标准差),16%存在认知障碍;淀粉样蛋白PET阴性亚组277例,所有扫描时淀粉样蛋白斑块负荷水平低且认知正常。
主要发现
- 脑脊液Aβ42/Aβ40、血浆Aβ42/Aβ40、脑脊液pT217/T217和淀粉样蛋白PET在估计症状发作前15-19年检测到变化。
- 血浆pT217/T217、脑脊液神经颗粒素、脑脊液SNAP-25、脑脊液sTREM2、血浆GFAP和血浆NfL在估计症状发作前12-14年检测到变化。
- 脑脊液p205/T205、脑脊液YKL-40、海马体积和认知指标在估计症状发作前7-9年检测到变化。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: A clock relating amyloid positron emission tomography (PET) to time was used to estimate the timing of biomarker changes in sporadic Alzheimer disease (AD). METHODS: Research participants were included who underwent cerebrospinal fluid (CSF) collection within 2 years of amyloid PET. The ages at amyloid onset and AD symptom onset were estimated for each individual. The timing of change for plasma, CSF, imaging, and cognitive measures was calculated by comparing restricted cubic splines of cross-sectional data from the amyloid PET positive and negative groups. RESULTS: The amyloid PET positive sub-cohort (n = 118) had an average age of 70.4 ± 7.4 years (mean ± standard deviation) and 16% were cognitively impaired. The amyloid PET negative sub-cohort (n = 277) included individuals with low levels of amyloid plaque burden at all scans who were cognitively unimpaired at the time of the scans. Biomarker changes were detected 15-19 years before estimated symptom onset for CSF Aβ42/Aβ40, plasma Aβ42/Aβ40, CSF pT217/T217, and amyloid PET; 12-14 years before estimated symptom onset for plasma pT217/T217, CSF neurogranin, CSF SNAP-25, CSF sTREM2, plasma GFAP, and plasma NfL; and 7-9 years before estimated symptom onset for CSF pT205/T205, CSF YKL-40, hippocampal volumes, and cognitive measures. INTERPRETATION: The use of an amyloid clock enabled visualization and analysis of biomarker changes as a function of estimated years from symptom onset in sporadic AD. This study demonstrates that estimated years from symptom onset based on an amyloid clock can be used as a continuous staging measure for sporadic AD and aligns with findings in autosomal dominant AD. ANN NEUROL 2024;95:951-965.
引用
- Li Y, Yen D, Hendrix RD, et al. Timing of Biomarker Changes in Sporadic Alzheimer's Disease in Estimated Years from Symptom Onset. Ann Neurol. 2024. PMID: 38400792. doi:10.1002/ana.26891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。